-
1
-
-
77954692660
-
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
-
Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-33.
-
(2010)
JAMA
, vol.304
, pp. 321-333
-
-
Thompson, M.A.1
Aberg, J.A.2
Cahn, P.3
Montaner, J.S.4
Rizzardini, G.5
-
2
-
-
23044496716
-
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
-
Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366: 378-84.
-
(2005)
Lancet
, vol.366
, pp. 378-384
-
-
Sterne, J.A.1
Hernan, M.A.2
Ledergerber, B.3
Tilling, K.4
Weber, R.5
-
3
-
-
30944468562
-
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
-
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-60.
-
(2006)
N Engl J Med
, vol.354
, pp. 251-260
-
-
Gallant, J.E.1
DeJesus, E.2
Arribas, J.R.3
Pozniak, A.L.4
Gazzard, B.5
-
4
-
-
27444444039
-
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)
-
Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, et al. (2005) Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 40: 280-87.
-
(2005)
J Acquir Immune Defic Syndr
, vol.40
, pp. 280-287
-
-
Arribas, J.R.1
Pulido, F.2
Delgado, R.3
Lorenzo, A.4
Miralles, P.5
-
5
-
-
33845716442
-
A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy
-
Pierone G Jr, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, et al. (2006) A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 7: 237-45.
-
(2006)
HIV Clin Trials
, vol.7
, pp. 237-245
-
-
Pierone Jr., G.1
Mieras, J.2
Bulgin-Coleman, D.3
Kantor, C.4
Shearer, J.5
-
6
-
-
77950957548
-
Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?
-
Battegay M, Bucher HC, (2010) Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy? AIDS 24: 1057-59.
-
(2010)
AIDS
, vol.24
, pp. 1057-1059
-
-
Battegay, M.1
Bucher, H.C.2
-
7
-
-
0344760902
-
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
-
Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services
-
Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
-
(2009)
-
-
-
8
-
-
78649382207
-
Clinical Management and Treatment of HIV Infected Adults in Europe
-
European AIDS Clinical Society, Accessed 2011 June 16
-
European AIDS Clinical Society (2009) Clinical Management and Treatment of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/guidelines.asp. Accessed 2011 June 16.
-
(2009)
-
-
-
10
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
-
(2003)
BMJ
, vol.327
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
Altman, D.G.4
-
11
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-58.
-
(2002)
Stat Med
, vol.21
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
12
-
-
0034823867
-
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis
-
Sterne JA, Egger M, (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54: 1046-55.
-
(2001)
J Clin Epidemiol
, vol.54
, pp. 1046-1055
-
-
Sterne, J.A.1
Egger, M.2
-
13
-
-
78649775786
-
Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials
-
Soonawala D, Middelburg RA, Egger M, Vandenbroucke JP, Dekkers OM, (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. Int J Epidemiol 39: 1567-81.
-
(2010)
Int J Epidemiol
, vol.39
, pp. 1567-1581
-
-
Soonawala, D.1
Middelburg, R.A.2
Egger, M.3
Vandenbroucke, J.P.4
Dekkers, O.M.5
-
14
-
-
33644789375
-
Quality of reporting of noninferiority and equivalence randomized trials
-
Le HA, Giraudeau B, Baron G, Ravaud P, (2006) Quality of reporting of noninferiority and equivalence randomized trials. JAMA 295: 1147-51.
-
(2006)
JAMA
, vol.295
, pp. 1147-1151
-
-
Le, H.A.1
Giraudeau, B.2
Baron, G.3
Ravaud, P.4
-
15
-
-
0034077203
-
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group
-
Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, et al. (2000) The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 14: 405-13.
-
(2000)
AIDS
, vol.14
, pp. 405-413
-
-
Gisolf, E.H.1
Jurriaans, S.2
Pelgrom, J.3
van Wanzeele, F.4
van der Ende, M.E.5
-
16
-
-
0035870551
-
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
-
Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, et al. (2001) A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr 26: 458-61.
-
(2001)
J Acquir Immune Defic Syndr
, vol.26
, pp. 458-461
-
-
Eron, J.J.1
Haubrich, R.2
Lang, W.3
Pagano, G.4
Millard, J.5
-
17
-
-
0034457420
-
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group
-
Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ, (2000) Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 31: 1234-39.
-
(2000)
Clin Infect Dis
, vol.31
, pp. 1234-1239
-
-
Gisolf, E.H.1
Dreezen, C.2
Danner, S.A.3
Weel, J.L.4
Weverling, G.J.5
-
18
-
-
38149028378
-
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
-
Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, et al. (2008) Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22: 385-93.
-
(2008)
AIDS
, vol.22
, pp. 385-393
-
-
Delfraissy, J.F.1
Flandre, P.2
Delaugerre, C.3
Ghosn, J.4
Horban, A.5
-
19
-
-
47649119335
-
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
-
Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-40.
-
(2008)
J Infect Dis
, vol.198
, pp. 234-240
-
-
Cameron, D.W.1
da Silva, B.A.2
Arribas, J.R.3
Myers, R.A.4
Bellos, N.C.5
-
20
-
-
0032578860
-
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team
-
Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, et al. (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 339: 1261-68.
-
(1998)
N Engl J Med
, vol.339
, pp. 1261-1268
-
-
Havlir, D.V.1
Marschner, I.C.2
Hirsch, M.S.3
Collier, A.C.4
Tebas, P.5
-
21
-
-
0034007440
-
Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3
-
Lewi DS, Suleiman JM, Uip DE, Pedro RJ, Souza RA, et al. (2000) Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. Rev Inst Med Trop Sao Paulo 42: 27-36.
-
(2000)
Rev Inst Med Trop Sao Paulo
, vol.42
, pp. 27-36
-
-
Lewi, D.S.1
Suleiman, J.M.2
Uip, D.E.3
Pedro, R.J.4
Souza, R.A.5
-
22
-
-
0032883118
-
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
-
Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, et al. (1999) A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 180: 659-665.
-
(1999)
J Infect Dis
, vol.180
, pp. 659-665
-
-
Hirsch, M.1
Steigbigel, R.2
Staszewski, S.3
Mellors, J.4
Scerpella, E.5
-
23
-
-
0032899327
-
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
-
Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, et al. (1999) Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 179: 808-16.
-
(1999)
J Infect Dis
, vol.179
, pp. 808-816
-
-
Murphy, R.L.1
Gulick, R.M.2
DeGruttola, V.3
D'Aquila, R.T.4
Eron, J.J.5
-
24
-
-
79960469733
-
Boosted protease inhbitor monotherapy as maintenance second-line-retroviral therapy in Africa
-
July 18-23, 2010 Vienna Abstract LPBE16
-
Gilks CF, Walker AS, Munderi P, Reid A, Ssali F, et al. (2010) Boosted protease inhbitor monotherapy as maintenance second-line-retroviral therapy in Africa. XVIII Internationa AIDS Conference July 18-23, 2010 Vienna Abstract LPBE16.
-
(2010)
XVIII Internationa AIDS Conference
-
-
Gilks, C.F.1
Walker, A.S.2
Munderi, P.3
Reid, A.4
Ssali, F.5
-
29
-
-
79960464997
-
Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO) NCT01189695
-
Bamrasnaradura Infectious Diseases Institute
-
Bamrasnaradura Infectious Diseases Institute (2010) Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (BIDI-MONO) NCT01189695.
-
(2010)
-
-
-
32
-
-
79960463195
-
Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs.Triple Therapy With a Boosted Protease Inhibitor (QoLKAMON) NCT01166477
-
Sociedad Andaluza de Enfermedades Infecciosas
-
Sociedad Andaluza de Enfermedades Infecciosas (2010) Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs.Triple Therapy With a Boosted Protease Inhibitor (QoLKAMON) NCT01166477.
-
(2010)
-
-
-
33
-
-
79960440282
-
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy NCT00437476
-
IRCCS San Raffaele
-
IRCCS San Raffaele (2010) Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy NCT00437476.
-
(2010)
-
-
-
35
-
-
79960447410
-
A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy ISRCTN04857074
-
Medical Research Council Clinical Trials Unit LU
-
Medical Research Council Clinical Trials Unit LU (2010) A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy ISRCTN04857074.
-
(2010)
-
-
-
36
-
-
79960442621
-
The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: An unblinded, multicentre, randomised controlled trial ISRCTN04857074
-
Guy's & St.Thomas' NHS Foundation Trust (UK)
-
Guy's & St.Thomas' NHS Foundation Trust (UK) (2010) The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: An unblinded, multicentre, randomised controlled trial ISRCTN04857074.
-
(2010)
-
-
-
37
-
-
79960440282
-
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy NCT00437684
-
IRCCS San Raffaele
-
IRCCS San Raffaele (2010) Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy NCT00437684.
-
(2010)
-
-
-
38
-
-
79960444501
-
HAART followed by maintenance with monotherapy - Kaletra (MAIMOKA) ISRCTN45284754
-
Vrije University Medical Centre (VUMC) (The Netherlands)
-
Vrije University Medical Centre (VUMC) (The Netherlands) (2010) HAART followed by maintenance with monotherapy- Kaletra (MAIMOKA) ISRCTN45284754.
-
(2010)
-
-
-
39
-
-
79960455612
-
Lopinavir Monotherapy get title
-
August 3-8, 2008, Mexico City, Mexico Abstract CDB0193
-
Waters L, Jackson A, Singh K, Higgs C, Mandalia S, et al. (2008) Lopinavir Monotherapy get title. XVII International AIDS Conference August 3-8, 2008, Mexico City, Mexico Abstract CDB0193.
-
(2008)
XVII International AIDS Conference
-
-
Waters, L.1
Jackson, A.2
Singh, K.3
Higgs, C.4
Mandalia, S.5
-
40
-
-
37549030881
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
-
Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, et al. (2008) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22: F1-F9.
-
(2008)
AIDS
, vol.22
, pp. 1-9
-
-
Pulido, F.1
Arribas, J.R.2
Delgado, R.3
Cabrero, E.4
Gonzalez-Garcia, J.5
-
41
-
-
77957231616
-
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir
-
Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, et al. (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24: 2347-54.
-
(2010)
AIDS
, vol.24
, pp. 2347-2354
-
-
Gutmann, C.1
Cusini, A.2
Gunthard, H.F.3
Fux, C.4
Hirschel, B.5
-
42
-
-
76749154576
-
Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)
-
Nunes EP, Santini de OM, Mercon M, Zajdenverg R, Faulhaber JC, et al. (2009) Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 10: 368-74.
-
(2009)
HIV Clin Trials
, vol.10
, pp. 368-374
-
-
Nunes, E.P.1
de Santini, O.M.2
Mercon, M.3
Zajdenverg, R.4
Faulhaber, J.C.5
-
43
-
-
79960460405
-
Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1
-
12th European AIDS Conference (EACS) November 11-14, 2009 Cologne, Germany Abstract P/S4 3
-
Cahn P, Andrade-Villanueva J, Sierra-Madero J, Casetti I, Junod P, et al. (2010) Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1. 12th European AIDS Conference (EACS) November 11-14, 2009 Cologne, Germany Abstract P/S4 3.
-
(2010)
-
-
Cahn, P.1
Andrade-Villanueva, J.2
Sierra-Madero, J.3
Casetti, I.4
Junod, P.5
-
44
-
-
77957872525
-
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: hte KALESOLO trial
-
Meynard JL, Bouteloup V, Landman R, Bonnard P, Baillat V, et al. (2010) Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: hte KALESOLO trial. J Antimicrob Chemother 65: 2436-44.
-
(2010)
J Antimicrob Chemother
, vol.65
, pp. 2436-2444
-
-
Meynard, J.L.1
Bouteloup, V.2
Landman, R.3
Bonnard, P.4
Baillat, V.5
-
45
-
-
77957230936
-
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136
-
Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, et al. (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24: 2365-74.
-
(2010)
AIDS
, vol.24
, pp. 2365-2374
-
-
Katlama, C.1
Valantin, M.A.2
Algarte-Genin, M.3
Duvivier, C.4
Lambert-Niclot, S.5
-
46
-
-
74249086332
-
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
-
Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, et al. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24: 223-30.
-
(2010)
AIDS
, vol.24
, pp. 223-230
-
-
Arribas, J.R.1
Horban, A.2
Gerstoft, J.3
Fatkenheuer, G.4
Nelson, M.5
-
47
-
-
78249266604
-
Saqinavir/ritonavir monotherapy as a new nucleoside sparing maintenance strategy in long-term virologically suppressed HIV-infected patients
-
Echeverria P, Domingo P, Gutierrez M, Mateo G, Fuster M, et al. (2010) Saqinavir/ritonavir monotherapy as a new nucleoside sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. Curr HIV Res 8: 467-70.
-
(2010)
Curr HIV Res
, vol.8
, pp. 467-470
-
-
Echeverria, P.1
Domingo, P.2
Gutierrez, M.3
Mateo, G.4
Fuster, M.5
-
48
-
-
79960455994
-
Lopinavir/ritonavir as single-drug for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study): 72 weeks analysis
-
10th European AIDS Conference/EACS, November 17-20, 2005 Dublin, Irleand Abstract PE7 5/5
-
Pulido F, Arribas J, Delgado R, Pano JR, Lorenzo A, et al. (2010) Lopinavir/ritonavir as single-drug for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study): 72 weeks analysis. 10th European AIDS Conference/EACS, November 17-20, 2005 Dublin, Irleand Abstract PE7 5/5.
-
(2010)
-
-
Pulido, F.1
Arribas, J.2
Delgado, R.3
Pano, J.R.4
Lorenzo, A.5
-
49
-
-
67649207695
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
-
Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, et al. (2009) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 51: 147-52.
-
(2009)
J Acquir Immune Defic Syndr
, vol.51
, pp. 147-152
-
-
Arribas, J.R.1
Delgado, R.2
Arranz, A.3
Munoz, R.4
Portilla, J.5
-
50
-
-
79960438105
-
The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r +2NRTIs, for patients with HIV RNA <50 copies/mL at baseline
-
XVIII Internationa AIDS Conference, July 18-23, 2010 Vienna, Austria Abstract TBLBB209
-
Rieger A, Banhegyi D, Schmidt W, Arribas J, Hill A, et al. (2010) The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r +2NRTIs, for patients with HIV RNA <50 copies/mL at baseline. XVIII Internationa AIDS Conference, July 18-23, 2010 Vienna, Austria Abstract TBLBB209.
-
(2010)
-
-
Rieger, A.1
Banhegyi, D.2
Schmidt, W.3
Arribas, J.4
Hill, A.5
-
51
-
-
0029987569
-
Trials to assess equivalence: the importance of rigorous methods
-
Jones B, Jarvis P, Lewis JA, Ebbutt AF, (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ 313: 36-39.
-
(1996)
BMJ
, vol.313
, pp. 36-39
-
-
Jones, B.1
Jarvis, P.2
Lewis, J.A.3
Ebbutt, A.F.4
-
52
-
-
38949173080
-
Current issues in non-inferiority trials
-
Fleming TR, (2008) Current issues in non-inferiority trials. Stat Med 27: 317-32.
-
(2008)
Stat Med
, vol.27
, pp. 317-332
-
-
Fleming, T.R.1
-
53
-
-
77954882772
-
-
U.S.Department of Health and Human Services Food and Drug Administration,. Accessed 2011 June 16
-
U.S.Department of Health and Human Services Food and Drug Administration (2010) Guidance for Industry, Non-inferiority Clinical Trials. http://www.fda.gov/../GuidanceComplianceRegulatoryInformation/Guidances/ucm202140.pdf. Accessed 2011 June 16.
-
(2010)
Guidance for Industry, Non-inferiority Clinical Trials
-
-
-
54
-
-
43649090700
-
Designing and interpreting HIV noninferiority trials in naive and experienced patients
-
Hill A, Sabin C, (2008) Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 22: 913-21.
-
(2008)
AIDS
, vol.22
, pp. 913-921
-
-
Hill, A.1
Sabin, C.2
-
55
-
-
76749136667
-
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy
-
Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, et al. (2010) Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50: 773-78.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 773-778
-
-
Canestri, A.1
Lescure, F.X.2
Jaureguiberry, S.3
Moulignier, A.4
Amiel, C.5
-
56
-
-
47649119335
-
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
-
Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-40.
-
(2008)
J Infect Dis
, vol.198
, pp. 234-240
-
-
Cameron, D.W.1
da Silva, B.A.2
Arribas, J.R.3
Myers, R.A.4
Bellos, N.C.5
-
57
-
-
79960464057
-
Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONO-ANRS 136 randomized trial: Results at 48 weeks
-
17th Conerence on Retroviruses and Opportunistic Infections, February 16-19,2010, San Franciso, USA Abstract 721
-
Valantin MA, Flandre P, Kolta S, Duvivier C, Algarte-Genin M, et al. (2010) Fat tissue distribution changes in HIV-infected patients with viral suppression treated with DRV/r monotherapy vs 2 NRTI + DRV/r in the MONO-ANRS 136 randomized trial: Results at 48 weeks. 17th Conerence on Retroviruses and Opportunistic Infections, February 16-19,2010, San Franciso, USA Abstract 721.
-
(2010)
-
-
Valantin, M.A.1
Flandre, P.2
Kolta, S.3
Duvivier, C.4
Algarte-Genin, M.5
-
58
-
-
68449093191
-
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
-
van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, et al. (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23: 1367-76.
-
(2009)
AIDS
, vol.23
, pp. 1367-1376
-
-
van Vonderen, M.G.1
Lips, P.2
van Agtmael, M.A.3
Hassink, E.A.4
Brinkman, K.5
-
59
-
-
79551583044
-
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial
-
Hansen A, Obel N, Nielsen H, Pedersen C, Gerstoft J, (2010) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 12: 157-65.
-
(2010)
HIV Med
, vol.12
, pp. 157-165
-
-
Hansen, A.1
Obel, N.2
Nielsen, H.3
Pedersen, C.4
Gerstoft, J.5
-
60
-
-
34848824668
-
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
-
Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, et al. (2007) Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 45: 1062-70.
-
(2007)
Clin Infect Dis
, vol.45
, pp. 1062-1070
-
-
Schackman, B.R.1
Scott, C.A.2
Sax, P.E.3
Losina, E.4
Wilkin, T.J.5
-
61
-
-
79960440111
-
Cost effectiveness of switching to second line therapy with lopinavir/ritonavir (LPV/r) in Kenya and Uganda
-
5th International AIDS Society Conference on Pathogenesis, Treatment and Prevention, July 19-22, 2009, Cape Town, South Africa Abstract MOPED012
-
Simpson KN, Dietz B, Rahim B, S.Rayagopalan R, (2009) Cost effectiveness of switching to second line therapy with lopinavir/ritonavir (LPV/r) in Kenya and Uganda. 5th International AIDS Society Conference on Pathogenesis, Treatment and Prevention, July 19-22, 2009, Cape Town, South Africa Abstract MOPED012.
-
(2009)
-
-
Simpson, K.N.1
Dietz, B.2
Rahim, B.3
Rayagopalan, S.R.4
|